The World Health Organization (WHO) announced that two potential vaccines targeting the Bundibugyo strain of Ebola are expected to enter clinical trials in the Democratic Republic of the Congo (DRC) next week, as the country continues to grapple with a major outbreak.
WHO Director-General Tedros Adhanom Ghebreyesus said the two vaccine candidates had been specifically developed to tackle the Bundibugyo strain, for which no approved vaccine or treatment is currently available.
“We expect two candidate vaccines, specifically developed against the Bundibugyo virus, to be tested as soon as possible, possibly by next week,” Tedros told a press conference in Geneva.
According to WHO numbers, the outbreak has resulted in 11,376 infections and 5,568 deaths in the Central African country.
The DRC officially declared the Ebola outbreak on May 15, with the current epidemic caused by the Bundibugyo strain of the virus.
Tedros said the outbreak continues to generate between 400 and 500 new cases every week, adding that two-thirds of confirmed deaths are still occurring outside treatment centres.
The planned vaccine trials come amid ongoing efforts to contain the outbreak and improve access to medical care, particularly in affected communities.

